273 related articles for article (PubMed ID: 18822200)
1. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China].
Shi KQ; Zhang DZ; Guo SH; He H; Wang ZY; Shi XF; Zeng WQ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2008 Sep; 16(9):641-5. PubMed ID: 18822200
[TBL] [Abstract][Full Text] [Related]
2. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
3. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients].
Huang J; Chen XP; Chen XF; Chen WL; Chen R; Ma XJ; Luo XD
Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):178-81. PubMed ID: 21586234
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
5. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
[TBL] [Abstract][Full Text] [Related]
7. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
Lv GC; Ma WJ; Ying LJ; Jin X; Zheng L; Yang YD
World J Gastroenterol; 2010 Aug; 16(32):4095-9. PubMed ID: 20731026
[TBL] [Abstract][Full Text] [Related]
9. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
Suh DJ; Um SH; Herrmann E; Kim JH; Lee YS; Lee HJ; Lee MS; Lee YJ; Bao W; Lopez P; Lee HC; Avila C; Zeuzem S
Antimicrob Agents Chemother; 2010 Mar; 54(3):1242-7. PubMed ID: 20028815
[TBL] [Abstract][Full Text] [Related]
10. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24-week therapy with pegylated interferon-α-2a].
Luo XD; Chen XP; Chen R; Chen XF; Huang J
Zhonghua Gan Zang Bing Za Zhi; 2016 Apr; 24(4):241-5. PubMed ID: 27470620
[TBL] [Abstract][Full Text] [Related]
13. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
[TBL] [Abstract][Full Text] [Related]
14. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Su QM; Ye XG
World J Gastroenterol; 2012 Nov; 18(43):6290-301. PubMed ID: 23180951
[TBL] [Abstract][Full Text] [Related]
15. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
17. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.
Seto WK; Lai CL; Fung J; Wong DK; Yuen JC; Hung IF; Yuen MF
J Hepatol; 2011 Sep; 55(3):522-528. PubMed ID: 21147187
[TBL] [Abstract][Full Text] [Related]
18. [The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].
Jia JD; Hou JL; Yin YK; Xu DZ; Tan DM; Niu JQ; Zhou XQ; Wang YM; Zhu LM; He YW; Ren H; Wan MB; Chen CW; Wu SM; Chen YG; Xu JZ; Wang QH; Wei L; Ma H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):342-5. PubMed ID: 17524265
[TBL] [Abstract][Full Text] [Related]
19. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
Luo XD; Chen XP; Chen XF
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):896-901. PubMed ID: 29325289
[No Abstract] [Full Text] [Related]
20. [Clinical antiviral effects of telbivudine in patients with chronic hepatitis B].
Xu Y; Wang JB; Ji SW; Zhang YG; Siqingtu NL; Zhao P; Guo HH; Li Y; Jiao J; Zhou CY
Zhonghua Gan Zang Bing Za Zhi; 2010 Apr; 18(4):259-62. PubMed ID: 20460043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
